Cargando…

EGFR mutation types and abundance were associated with the overall survival of advanced lung adenocarcinoma patients receiving first-line tyrosine kinase inhibitors

BACKGROUND: Epidermal growth factor receptor tyrosine kinases inhibitors (EGFR-TKIs) are currently recognized as the standard treatment for advanced non-small cell lung cancer (NSCLC) patients with EGFR mutations. Clinically found patients with different EGFR mutational status have different prognos...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yang, Wang, Hongyan, Yang, Sen, Yang, Yuanyuan, Wu, Yufeng, He, Zhen, Ma, Shuxiang, Mo, Yuqing, Chen, Haiyang, Wang, Qiming, Ge, Hong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9264099/ https://www.ncbi.nlm.nih.gov/pubmed/35813717 http://dx.doi.org/10.21037/jtd-22-755

Ejemplares similares

Impact of MET alterations on targeted therapy with EGFR-tyrosine kinase inhibitors for EGFR-mutant lung cancer
por: Zhang, Zhe, et al.
Publicado: (2019)

Dynamic changes of acquired T790M mutation and small cell lung cancer transformation in a patient with EGFR-mutant adenocarcinoma after first- and third-generation EGFR-TKIs: a case report
por: Ma, Shuxiang, et al.
Publicado: (2020)

First‐line epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor alone or with whole‐brain radiotherapy for brain metastases in patients with EGFR‐mutated lung adenocarcinoma
por: Chen, Yongshun, et al.
Publicado: (2016)

EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
por: Yang, Jiyoul, et al.
Publicado: (2018)

Improved survival in patients with unresectable stage III EGFR ‐mutant adenocarcinoma with upfront EGFR‐tyrosine kinase inhibitors
por: Wang, Sheng‐Yuan, et al.
Publicado: (2021)

EGFR-activating mutations, DNA copy number abundance of ErbB family, and prognosis in lung adenocarcinoma
por: Chen, Hsuan-Yu, et al.
Publicado: (2016)

EGFR exon 20 insertion mutations in advanced non-small-cell lung cancer: current status and perspectives
por: Hou, Jiabao, et al.
Publicado: (2022)

Concomitant Pulmonary Tuberculosis Impair Survival in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Lung Adenocarcinoma Patients Receiving EGFR-Tyrosine Kinase Inhibitor
por: Xie, Yalin, et al.
Publicado: (2021)

A case report of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with T790M mutation and epithelial-to-mesenchymal transition
por: Zhang, Nana, et al.
Publicado: (2017)

Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
por: Wu, Shang-Gin, et al.
Publicado: (2017)

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
por: Wu, Shang-Gin, et al.
Publicado: (2016)

EGFR DNA Methylation Correlates With EGFR Expression, Immune Cell Infiltration, and Overall Survival in Lung Adenocarcinoma
por: Xu, Zhanyu, et al.
Publicado: (2021)

MET inhibitors for targeted therapy of EGFR TKI-resistant lung cancer
por: Wang, Qiming, et al.
Publicado: (2019)

Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis
por: Kuan, Feng-Che, et al.
Publicado: (2015)

Tyrosine kinase inhibitor acquired resistance mechanism alternates between EGFR and ALK in a lung adenocarcinoma patient
por: Hu, Yijuan, et al.
Publicado: (2019)

Anaplastic lymphoma kinase rearrangement may increase the incidence of venous thromboembolism by increasing tissue factor expression in advanced lung adenocarcinoma
por: Yang, Sen, et al.
Publicado: (2020)

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma
por: Wu, Chiao-En, et al.
Publicado: (2022)

Prior EGFR tyrosine-kinase inhibitor therapy did not influence the efficacy of subsequent pemetrexed plus platinum in advanced chemonaïve patients with EGFR-mutant lung adenocarcinoma
por: Tseng, Jeng-Sen, et al.
Publicado: (2014)

The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors
por: Kim, Hyungjin, et al.
Publicado: (2017)

Uncommon EGFR mutations in lung adenocarcinoma: features and response to tyrosine kinase inhibitors
por: Brindel, Aurélien, et al.
Publicado: (2020)

NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR–TKI Resistance in Lung Adenocarcinoma
por: Zhang, Youwei, et al.
Publicado: (2019)

Poorer prognosis in Taiwanese female ever smokers with stage IV lung adenocarcinoma who were readministered a tyrosine kinase inhibitor
por: Yang, Chih-Jen, et al.
Publicado: (2016)

Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
por: Chen, Po-Yen, et al.
Publicado: (2021)

High PHLPP1 expression levels predicts longer time of acquired resistance to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Xie, Youyou, et al.
Publicado: (2017)

Efficacy of pemetrexed and carboplatin with or without bevacizumab in lung adenocarcinoma patients with EGFR non‐T790M mutations after progression on first‐line EGFR‐tyrosine kinase inhibitors
por: Jiang, Zhansheng, et al.
Publicado: (2018)

The clinicopathological and molecular characteristics of resected EGFR‐mutant lung adenocarcinoma
por: Zhou, Wensheng, et al.
Publicado: (2022)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
por: Pan, Yingying, et al.
Publicado: (2019)

Cell-free DNA from cerebrospinal fluid can be used to detect the EGFR mutation status of lung adenocarcinoma patients with central nervous system metastasis
por: Liu, Yang, et al.
Publicado: (2021)

Efficacy of Osimertinib After Progression of First-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) in EGFR-Mutated Lung Adenocarcinoma: A Real-World Study in Chinese Patients
por: Xu, Ziyi, et al.
Publicado: (2022)

B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors
por: Yang, Ying, et al.
Publicado: (2022)

MUSASHI‐2 confers resistance to third‐generation EGFR‐tyrosine kinase inhibitor osimertinib in lung adenocarcinoma
por: Yiming, Reheman, et al.
Publicado: (2021)

Heart Dosimetric Parameters Were Associated With Cardiac Events and Overall Survival for Patients With Locally Advanced Esophageal Cancer Receiving Definitive Radiotherapy
por: Cai, Guoxin, et al.
Publicado: (2020)

Assessment of EGFR gene mutations in circulating free DNA in monitoring of response to EGFR tyrosine kinase inhibitors in patients with lung adenocarcinoma
por: Nicoś, Marcin, et al.
Publicado: (2019)

Sequential treatment in advanced epidermal growth factor receptor-mutated lung adenocarcinoma patients receiving first-line bevacizumab combined with 1st/2nd-generation EGFR-tyrosine kinase inhibitors
por: Hsu, Ping-Chih, et al.
Publicado: (2023)

A real-world study comparing perioperative chemotherapy and EGFR-tyrosine kinase inhibitors for treatment of resected stage III EGFR-mutant adenocarcinoma
por: Chen, Chieh-Lung, et al.
Publicado: (2023)

The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition
por: Wu, Shang-Gin, et al.
Publicado: (2016)

Hepatocyte growth factor reduces sensitivity to the epidermal growth factor receptor-tyrosine kinase inhibitor, gefitinib, in lung adenocarcinoma cells harboring wild-type EGFR
por: Yang, Hua, et al.
Publicado: (2016)

The overall survival benefit in Chinese ALK(+) NSCLC patients received targeted therapies
por: Tian, Guangming, et al.
Publicado: (2022)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
por: Miyoshi, Seigo, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_vpsfmp7duiv4i43gj1r8dm2imf